• Je něco špatně v tomto záznamu ?

Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

I. Diouf, CB. Malpas, S. Sharmin, I. Roos, D. Horakova, EK. Havrdova, F. Patti, V. Shaygannejad, S. Ozakbas, G. Izquierdo, S. Eichau, M. Onofrj, A. Lugaresi, R. Alroughani, A. Prat, M. Girard, P. Duquette, M. Terzi, C. Boz, F. Grand'Maison, S....

. 2023 ; 30 (4) : 1014-1024. [pub] 20230216

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003683

BACKGROUND AND PURPOSE: This study assessed the effect of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS). METHODS: We extracted data from 61,810 patients from 135 centers across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS, follow-up ≥ 1 year, and Expanded Disability Status Scale (EDSS) score ≥ 3, with ≥1 score recorded per year. Marginal structural models with interaction terms were used to compare the hazards of 12-month confirmed worsening and improvement of disability, and the incidence of relapses between treated and untreated patients stratified by their characteristics. RESULTS: Among 24,344 patients with relapsing MS, those on DMTs experienced 48% reduction in relapse incidence (hazard ratio [HR] = 0.52, 95% confidence interval [CI] = 0.45-0.60), 46% lower risk of disability worsening (HR = 0.54, 95% CI = 0.41-0.71), and 32% greater chance of disability improvement (HR = 1.32, 95% CI = 1.09-1.59). The effect of DMTs on EDSS worsening and improvement and the risk of relapses was attenuated with more severe disability. The magnitude of the effect of DMT on suppressing relapses declined with higher prior relapse rate and prior cerebral magnetic resonance imaging activity. We did not find any evidence for the effect of age on the effectiveness of DMT. After inclusion of 1985 participants with progressive MS, the effect of DMT on disability mostly depended on MS phenotype, whereas its effect on relapses was driven mainly by prior relapse activity. CONCLUSIONS: DMT is generally most effective among patients with lower disability and in relapsing MS phenotypes. There is no evidence of attenuation of the effect of DMT with age.

Aarhus University Hospital Aarhus Denmark

Austin Health Melbourne Victoria Australia

Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino Avellino Italy

Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases Istanbul Turkey

Brain and Mind Centre Sydney New South Wales Australia

Center of Neuroimmunology Service of Neurology Hospital Clinic of Barcelona Barcelona Spain

Central Clinical School Monash University Melbourne Victoria Australia

CHUM Mississippi Center and University of Montreal Montreal Quebec Canada

CISSS Chaudière Appalache Levis Sainte Marie Quebec Canada

Cliniques Universitaires Saint Luc Louvain Brussels Belgium

CSSS Saint Jerome Saint Jerome Quebec Canada

Department of Medical and Surgical Sciences and Advanced Technologies GF Ingrassia Catania Italy

Department of Medicine and Surgery University of Parma Parma Italy

Department of Medicine CORe University of Melbourne Melbourne Victoria Australia

Department of Medicine Sultan Qaboos University Hospital Seeb Oman

Department of Neurology Alfred Hospital Melbourne Victoria Australia

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Czech Republic

Department of Neurology ASL3 Genovese Genoa Italy

Department of Neurology Centro Hospitalar Universitário de São João Porto Portugal

Department of Neurology Faculty of Medicine University of Debrecen Debrecen Hungary

Department of Neurology Neuroimmunology Centre Royal Melbourne Hospital Melbourne Victoria Australia

Department of Neurology Razi Hospital Manouba Tunisia

Department of Neurology School of Medicine Koc University Istanbul Turkey

Department of Neuroscience Azienda Ospedaliera Universitaria Modena Italy

Department of Neuroscience Imaging and Clinical Sciences D'Annunzio University Chieti Italy

Department of Rehabilitation ML Novarese Hospital Moncrivello Genoa Italy

Departments of Medicine and Clinical Research Neurologic Clinic and Policlinic University Hospital and University of Basel Basel Switzerland

Dipartimento di Scienze Biomediche e Neuromotorie Università di Bologna Bologna Italy

Division of Neurology Department of Medicine Amiri Hospital Sharq Kuwait

Dokuz Eylul University Konak Izmir Turkey

Flinders University Adelaide South Australia Australia

Garibaldi Hospital Catania Italy

Groene Hart Ziekenhuis Gouda the Netherlands

Hacettepe University Ankara Turkey

Haydarpasa Numune Training and Research Hospital Istanbul Turkey

Hospital de Galdakao Usansolo Galdakao Spain

Hospital Fernandez Buenos Aires Argentina

Hospital General Universitario de Alicante Alicante Spain

Hospital Italiano Buenos Aires Argentina

Hospital Universitario Virgen Macarena Seville Spain

Instituto de Investigacion Sanitaria Biodonostia Hospital Universitario Donostia San Sebastian Spain

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Mexico City Mexico

IRCCS Istituto delle Scienze Neurologiche di Bologna Bologna Italy

IRCCS Mondino Foundation Pavia Italy

Isfahan University of Medical Sciences Isfahan Iran

Jewish General Hospital Montreal Quebec Canada

Koc University Research Center for Translational Medicine Istanbul Turkey

KTU Medical Faculty Farabi Hospital Trabzon Turkey

Liverpool Hospital Sydney New South Wales Australia

Medical Center Leeuwarden Leeuwarden the Netherlands

Monash Medical Centre Melbourne Victoria Australia

Nehme and Therese Tohme Multiple Sclerosis Center American University of Beirut Medical Center Beirut Lebanon

Nemocnice Jihlava Jihlava Czech Republic

Neuro Rive Sud Quebec City Quebec Canada

Neurology Department King Fahad Specialist Hospital Dammam Dammam Saudi Arabia

Neurology Kasr Al Ainy MS Research Unit Cairo Egypt

Ospedali Riuniti di Salerno Salerno Italy

Postgraduate Institute of Medical Education and Research Chandigarh India

Rehabilitation and MS Center Overpelt and Hasselt University Hasselt Belgium

Royal Victoria Hospital Belfast UK

School of Medicine and Public Health University of Newcastle Newcastle New South Wales Australia

School of Medicine Ondokuz Mayis University Samsun Turkey

South East Trust Belfast UK

St Vincent's University Hospital Dublin Ireland

Trias and Pujol Brothers University Hospital Badalona Spain

Universidade Metropolitana de Santos Santos Brazil

University Hospital Geelong Geelong Victoria Australia

University Hospital Ghent Ghent Belgium

University Hospital Reina Sofia Cordoba Spain

University of Queensland Brisbane Queensland Australia

UOC Neurologia Azienda Sanitaria Unica Regionale Marche AV3 Macerata Italy

Waikato Hospital Hamilton New Zealand

Westmead Hospital Sydney New South Wales Australia

Zuyderland Medical Center Sittard Geleen the Netherlands

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003683
003      
CZ-PrNML
005      
20230425140809.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ene.15706 $2 doi
035    __
$a (PubMed)36692895
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Diouf, Ibrahima $u Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia
245    10
$a Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis / $c I. Diouf, CB. Malpas, S. Sharmin, I. Roos, D. Horakova, EK. Havrdova, F. Patti, V. Shaygannejad, S. Ozakbas, G. Izquierdo, S. Eichau, M. Onofrj, A. Lugaresi, R. Alroughani, A. Prat, M. Girard, P. Duquette, M. Terzi, C. Boz, F. Grand'Maison, S. Hamdy, P. Sola, D. Ferraro, P. Grammond, R. Turkoglu, K. Buzzard, O. Skibina, B. Yamout, A. Altintas, O. Gerlach, V. van Pesch, Y. Blanco, D. Maimone, J. Lechner-Scott, R. Bergamaschi, R. Karabudak, G. Iuliano, C. McGuigan, E. Cartechini, M. Barnett, S. Hughes, MJ. Sa, C. Solaro, L. Kappos, C. Ramo-Tello, E. Cristiano, S. Hodgkinson, D. Spitaleri, A. Soysal, T. Petersen, M. Slee, E. Butler, F. Granella, K. de Gans, P. McCombe, R. Ampapa, B. Van Wijmeersch, A. van der Walt, H. Butzkueven, J. Prevost, LGF. Sinnige, JL. Sanchez-Menoyo, S. Vucic, G. Laureys, L. Van Hijfte, D. Khurana, R. Macdonell, R. Gouider, T. Castillo-Triviño, O. Gray, E. Aguera-Morales, A. Al-Asmi, C. Shaw, N. Deri, T. Al-Harbi, Y. Fragoso, T. Csepany, A. Perez Sempere, I. Trevino-Frenk, J. Schepel, F. Moore, T. Kalincik
520    9_
$a BACKGROUND AND PURPOSE: This study assessed the effect of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS). METHODS: We extracted data from 61,810 patients from 135 centers across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS, follow-up ≥ 1 year, and Expanded Disability Status Scale (EDSS) score ≥ 3, with ≥1 score recorded per year. Marginal structural models with interaction terms were used to compare the hazards of 12-month confirmed worsening and improvement of disability, and the incidence of relapses between treated and untreated patients stratified by their characteristics. RESULTS: Among 24,344 patients with relapsing MS, those on DMTs experienced 48% reduction in relapse incidence (hazard ratio [HR] = 0.52, 95% confidence interval [CI] = 0.45-0.60), 46% lower risk of disability worsening (HR = 0.54, 95% CI = 0.41-0.71), and 32% greater chance of disability improvement (HR = 1.32, 95% CI = 1.09-1.59). The effect of DMTs on EDSS worsening and improvement and the risk of relapses was attenuated with more severe disability. The magnitude of the effect of DMT on suppressing relapses declined with higher prior relapse rate and prior cerebral magnetic resonance imaging activity. We did not find any evidence for the effect of age on the effectiveness of DMT. After inclusion of 1985 participants with progressive MS, the effect of DMT on disability mostly depended on MS phenotype, whereas its effect on relapses was driven mainly by prior relapse activity. CONCLUSIONS: DMT is generally most effective among patients with lower disability and in relapsing MS phenotypes. There is no evidence of attenuation of the effect of DMT with age.
650    _2
$a lidé $7 D006801
650    12
$a roztroušená skleróza $x terapie $7 D009103
650    12
$a chronicko-progresivní roztroušená skleróza $7 D020528
650    _2
$a imunoterapie $7 D007167
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a recidiva $7 D012008
650    12
$a relabující-remitující roztroušená skleróza $7 D020529
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Malpas, Charles B $u Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia $u Department of Neurology, Neuroimmunology Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia
700    1_
$a Sharmin, Sifat $u Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia
700    1_
$a Roos, Izanne $u Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia $u Department of Neurology, Neuroimmunology Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia $1 https://orcid.org/0000000303713666
700    1_
$a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Havrdova, Eva Kubala $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Patti, Francesco $u Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy $1 https://orcid.org/0000000269230846
700    1_
$a Shaygannejad, Vahid $u Isfahan University of Medical Sciences, Isfahan, Iran
700    1_
$a Ozakbas, Serkan $u Dokuz Eylul University, Konak/Izmir, Turkey
700    1_
$a Izquierdo, Guillermo $u Hospital Universitario Virgen Macarena, Seville, Spain
700    1_
$a Eichau, Sara $u Hospital Universitario Virgen Macarena, Seville, Spain
700    1_
$a Onofrj, Marco $u Department of Neuroscience, Imaging, and Clinical Sciences, D'Annunzio University, Chieti, Italy
700    1_
$a Lugaresi, Alessandra $u IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy $u Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy
700    1_
$a Alroughani, Raed $u Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait
700    1_
$a Prat, Alexandre $u CHUM Mississippi Center and University of Montreal, Montreal, Quebec, Canada
700    1_
$a Girard, Marc $u CHUM Mississippi Center and University of Montreal, Montreal, Quebec, Canada
700    1_
$a Duquette, Pierre $u CHUM Mississippi Center and University of Montreal, Montreal, Quebec, Canada
700    1_
$a Terzi, Murat $u School of Medicine, Ondokuz Mayis University, Samsun, Turkey $1 https://orcid.org/0000000235869115
700    1_
$a Boz, Cavit $u KTU Medical Faculty, Farabi Hospital, Trabzon, Turkey
700    1_
$a Grand'Maison, Francois $u Neuro Rive-Sud, Quebec City, Quebec, Canada
700    1_
$a Hamdy, Sherif $u Neurology, Kasr Al Ainy MS Research Unit, Cairo, Egypt
700    1_
$a Sola, Patrizia $u Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy
700    1_
$a Ferraro, Diana $u Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy $1 https://orcid.org/0000000348183806
700    1_
$a Grammond, Pierre $u CISSS Chaudière-Appalache, Levis, Sainte-Marie, Quebec, Canada
700    1_
$a Turkoglu, Recai $u Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
700    1_
$a Buzzard, Katherine $u Central Clinical School, Monash University, Melbourne, Victoria, Australia
700    1_
$a Skibina, Olga $u Central Clinical School, Monash University, Melbourne, Victoria, Australia
700    1_
$a Yamout, Bassem $u Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon $1 https://orcid.org/0000000225406651
700    1_
$a Altintas, Ayse $u Department of Neurology, School of Medicine, Koc University, Istanbul, Turkey $u Koc University Research Center for Translational Medicine, Istanbul, Turkey
700    1_
$a Gerlach, Oliver $u Zuyderland Medical Center, Sittard-Geleen, the Netherlands
700    1_
$a van Pesch, Vincent $u Cliniques Universitaires Saint-Luc, Louvain, Brussels, Belgium $1 https://orcid.org/0000000328859004
700    1_
$a Blanco, Yolanda $u Center of Neuroimmunology, Service of Neurology, Hospital Clinic of Barcelona, Barcelona, Spain $1 https://orcid.org/0000000218340498
700    1_
$a Maimone, Davide $u Garibaldi Hospital, Catania, Italy
700    1_
$a Lechner-Scott, Jeannette $u School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia
700    1_
$a Bergamaschi, Roberto $u IRCCS Mondino Foundation, Pavia, Italy
700    1_
$a Karabudak, Rana $u Hacettepe University, Ankara, Turkey
700    1_
$a Iuliano, Gerardo $u Ospedali Riuniti di Salerno, Salerno, Italy
700    1_
$a McGuigan, Chris $u St Vincent's University Hospital, Dublin, Ireland
700    1_
$a Cartechini, Elisabetta $u UOC Neurologia, Azienda Sanitaria Unica Regionale Marche-AV3, Macerata, Italy
700    1_
$a Barnett, Michael $u Brain and Mind Centre, Sydney, New South Wales, Australia
700    1_
$a Hughes, Stella $u Royal Victoria Hospital, Belfast, UK
700    1_
$a Sa, Maria José $u Department of Neurology, Centro Hospitalar Universitário de São João, Porto, Portugal
700    1_
$a Solaro, Claudio $u Department of Neurology, ASL3 Genovese, Genoa, Italy $u Department of Rehabilitation, ML Novarese Hospital Moncrivello, Genoa, Italy
700    1_
$a Kappos, Ludwig $u Departments of Medicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital and University of Basel, Basel, Switzerland
700    1_
$a Ramo-Tello, Cristina $u Trias and Pujol Brothers University Hospital, Badalona, Spain
700    1_
$a Cristiano, Edgardo $u Hospital Italiano, Buenos Aires, Argentina
700    1_
$a Hodgkinson, Suzanne $u Liverpool Hospital, Sydney, New South Wales, Australia
700    1_
$a Spitaleri, Daniele $u Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy
700    1_
$a Soysal, Aysun $u Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey
700    1_
$a Petersen, Thor $u Aarhus University Hospital, Aarhus, Denmark
700    1_
$a Slee, Mark $u Flinders University, Adelaide, South Australia, Australia
700    1_
$a Butler, Ernest $u Monash Medical Centre, Melbourne, Victoria, Australia
700    1_
$a Granella, Franco $u Department of Medicine and Surgery, University of Parma, Parma, Italy
700    1_
$a de Gans, Koen $u Groene Hart Ziekenhuis, Gouda, the Netherlands
700    1_
$a McCombe, Pamela $u University of Queensland, Brisbane, Queensland, Australia
700    1_
$a Ampapa, Radek $u Nemocnice Jihlava, Jihlava, Czech Republic
700    1_
$a Van Wijmeersch, Bart $u Rehabilitation and MS Center Overpelt and Hasselt University, Hasselt, Belgium
700    1_
$a van der Walt, Anneke $u Central Clinical School, Monash University, Melbourne, Victoria, Australia $u Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia
700    1_
$a Butzkueven, Helmut $u Austin Health, Melbourne, Victoria, Australia
700    1_
$a Prevost, Julie $u CSSS Saint-Jerome, Saint-Jerome, Quebec, Canada
700    1_
$a Sinnige, L G F $u Medical Center Leeuwarden, Leeuwarden, the Netherlands
700    1_
$a Sanchez-Menoyo, Jose Luis $u Hospital de Galdakao-Usansolo, Galdakao, Spain $1 https://orcid.org/0000000326348294
700    1_
$a Vucic, Steve $u Westmead Hospital, Sydney, New South Wales, Australia $1 https://orcid.org/0000000209564633
700    1_
$a Laureys, Guy $u University Hospital Ghent, Ghent, Belgium
700    1_
$a Van Hijfte, Liesbeth $u University Hospital Ghent, Ghent, Belgium
700    1_
$a Khurana, Dheeraj $u Postgraduate Institute of Medical Education and Research, Chandigarh, India
700    1_
$a Macdonell, Richard $u Austin Health, Melbourne, Victoria, Australia
700    1_
$a Gouider, Riadh $u Department of Neurology, Razi Hospital, Manouba, Tunisia
700    1_
$a Castillo-Triviño, Tamara $u Instituto de Investigacion Sanitaria Biodonostia, Hospital Universitario Donostia, San Sebastian, Spain
700    1_
$a Gray, Orla $u South East Trust, Belfast, UK
700    1_
$a Aguera-Morales, Eduardo $u University Hospital Reina Sofia, Cordoba, Spain
700    1_
$a Al-Asmi, Abdullah $u Department of Medicine, Sultan Qaboos University Hospital, Seeb, Oman
700    1_
$a Shaw, Cameron $u University Hospital Geelong, Geelong, Victoria, Australia
700    1_
$a Deri, Norma $u Hospital Fernandez, Buenos Aires, Argentina
700    1_
$a Al-Harbi, Talal $u Neurology Department, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia
700    1_
$a Fragoso, Yara $u Universidade Metropolitana de Santos, Santos, Brazil $1 https://orcid.org/000000018726089X
700    1_
$a Csepany, Tunde $u Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary $1 https://orcid.org/0000000283053209
700    1_
$a Perez Sempere, Angel $u Hospital General Universitario de Alicante, Alicante, Spain
700    1_
$a Trevino-Frenk, Irene $u Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
700    1_
$a Schepel, Jan $u Waikato Hospital, Hamilton, New Zealand
700    1_
$a Moore, Fraser $u Jewish General Hospital, Montreal, Quebec, Canada
700    1_
$a Kalincik, Tomas $u Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia $u Department of Neurology, Neuroimmunology Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia $1 https://orcid.org/0000000337781376 $7 xx0121848
773    0_
$w MED00001629 $t European journal of neurology $x 1468-1331 $g Roč. 30, č. 4 (2023), s. 1014-1024
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36692895 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140806 $b ABA008
999    __
$a ok $b bmc $g 1924387 $s 1189892
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 30 $c 4 $d 1014-1024 $e 20230216 $i 1468-1331 $m European journal of neurology $n Eur J Neurol $x MED00001629
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace